Trial Profile
A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2016
Price :
$35
*
At a glance
- Drugs Obicetrapib (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Xention
- 28 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Aug 2015 New trial record